Loading...
Bristol-Myers Squibb Company
BMY•NYSE
Healthcare
Drug Manufacturers - General
$48.43
$-0.51(-1.04%)
Bristol-Myers Squibb Company (BMY) AI-Powered Stock Analysis
See how Bristol-Myers Squibb Company scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerBristol-Myers Squibb Company (BMY) Stock Overall Grade
Bristol-Myers Squibb Company’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
B+
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to Bristol-Myers Squibb Company's overall stock rating.
Forecast
AScore
86/100Financial Growth
BScore
65/100Fundamental Growth
AScore
83/100Key Ratios
AScore
84/100Sector Comparison
B+Score
75/100Industry Comparison
A+Score
90/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
C+Score
58/100Bristol-Myers Squibb Company (BMY) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 86/100 (A), reflecting high confidence in its potential. Financial Growth (65/100, B) and Fundamental Growth (83/100, A) highlight its stability, while Key Ratios (84/100, A) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (58/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Bristol-Myers Squibb Company stock grade, including financials, comparisons, and forecasts.